Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Down – What’s Next?

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gapped down before the market opened on Thursday . The stock had previously closed at $152.82, but opened at $138.58. Palvella Therapeutics shares last traded at $140.9660, with a volume of 6,917 shares trading hands.

Analyst Ratings Changes

A number of research firms recently weighed in on PVLA. HC Wainwright lifted their price objective on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Stephens restated an “overweight” rating and set a $220.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Chardan Capital reaffirmed a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday. Finally, Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Palvella Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Price Performance

The firm’s 50 day moving average is $120.03 and its 200 day moving average is $111.35. The company has a market cap of $2.02 billion, a PE ratio of -33.79 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, analysts anticipate that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the transaction, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. This represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Several large investors have recently added to or reduced their stakes in PVLA. First Light Asset Management LLC purchased a new position in Palvella Therapeutics during the third quarter worth about $33,949,000. Summit Partners Public Asset Management LLC raised its holdings in shares of Palvella Therapeutics by 1,016.0% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after acquiring an additional 354,525 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Palvella Therapeutics by 202.0% during the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after acquiring an additional 330,847 shares during the last quarter. State Street Corp boosted its position in shares of Palvella Therapeutics by 206.3% during the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after acquiring an additional 283,211 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Palvella Therapeutics by 262.4% during the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock valued at $40,558,000 after acquiring an additional 280,573 shares during the last quarter. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.